Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$6.36
-0.3%
$4.79
$3.21
$7.18
$1.53B0.684.70 million shs2.37 million shs
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$14.76
+1.0%
$11.33
$6.38
$16.66
$1.43B1.471.34 million shs1.65 million shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$6.48
-2.6%
$7.11
$2.32
$9.30
$350.52M2.47577,530 shs181,855 shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$22.72
-1.4%
$24.53
$21.97
$71.71
$1.37B2.86927,005 shs456,346 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+3.07%+4.42%+51.18%+71.51%+3.74%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-1.68%-1.35%+37.54%+60.13%-1.62%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+0.30%+1.99%-12.38%-3.06%-25.03%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-1.28%-3.96%-4.63%-2.78%-47.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.1094 of 5 stars
3.52.00.04.41.92.50.6
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
2.8817 of 5 stars
3.63.00.00.02.91.70.6
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
0.8746 of 5 stars
2.31.00.00.02.21.70.0
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2.7307 of 5 stars
3.53.00.00.03.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$11.5080.82% Upside
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.14
Buy$19.6733.24% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.63
Moderate Buy$7.5716.84% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.08
Buy$86.90282.48% Upside

Current Analyst Ratings Breakdown

Latest FULC, AVDL, ARDX, and JANX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $20.00
8/18/2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$42.00
8/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $24.00
8/6/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.00
8/5/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
8/5/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.00
8/5/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$13.00 ➝ $14.00
7/30/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.00
7/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00 ➝ $12.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M4.59N/AN/A$0.58 per share10.97
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$169.12M8.47N/AN/A$0.93 per share15.87
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10.59M128.92N/AN/A$16.48 per share1.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.23N/A20.52N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.03N/A246.00N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)

Latest FULC, AVDL, ARDX, and JANX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$0.02$0.10+$0.08$0.10$60.28 million$68.13 million
8/7/2025Q2 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A
8/4/2025Q2 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million
7/29/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.44
4.30
4.03
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.79
2.38
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
24.42
24.42
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
47.03
47.03

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
5.20%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
7.00%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90240.98 million229.42 millionOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7097.10 million92.05 millionOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10054.09 million50.31 millionOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3060.09 million55.23 millionOptionable

Recent News About These Companies

BTIG Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$6.36 -0.02 (-0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$6.31 -0.05 (-0.79%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$14.76 +0.14 (+0.96%)
Closing price 04:00 PM Eastern
Extended Trading
$15.05 +0.29 (+1.99%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$6.48 -0.17 (-2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$6.59 +0.11 (+1.70%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$22.72 -0.33 (-1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$22.72 0.00 (0.00%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.